Exchange: NASDAQ·Updated 05:48 AM EDT
Latest Earnings Results: Q2 '26

Reported: Aug 11

Estimated EPS

-$0.21

Reported EPS

-$0.14

Surprise

+33.33%

Estimated Rev

$21.45M

Reported Rev

$22.73M

Surprise

+5.95%

$HBIO Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.64 down -28.00% YoY • Reported revenue of $22.73M up 11.13% YoY • Harvard Bioscience expects full-year 2026 revenue growth between 3% and 5%, with adjusted gross margin between 57% and 59% and adjusted EBITDA growth between 6% and 10% for the year.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '26
-$0.17
--
--
N/A
Q2 '26
-$0.21
-$0.14
33.33%
BEAT
Q1 '26
-$0.62
-$0.33
46.77%
BEAT
Q4 '25
$0.04
$0.00
-100.00%
MISSED
Q3 '25
$0.00
$0.00
-100.00%
MISSED

Advertisement|Remove ads.